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Abstract
The National Institute on Drug Abuse and Joint Institute for Biological Sciences at
the Oak Ridge National Laboratory hosted a meeting attended by a diverse group of
scientists with expertise in substance use disorders (SUDs), computational biology,
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and FAIR (Findability, Accessibility, Interoperability, and Reusability) data sharing. The
meeting's objective was to discuss and evaluate better strategies to integrate genetic,
epigenetic, and 'omics data across human and model organisms to achieve deeper
mechanistic insight into SUDs. Specific topics were to (a) evaluate the current state
of substance use genetics and genomics research and fundamental gaps, (b) identify
opportunities and challenges of integration and sharing across species and data types,
(c) identify current tools and resources for integration of genetic, epigenetic, and phenotypic data, (d) discuss steps and impediment related to data integration, and
(e) outline future steps to support more effective collaboration—particularly between
animal model research communities and human genetics and clinical research teams.
This review summarizes key facets of this catalytic discussion with a focus on new
opportunities and gaps in resources and knowledge on SUDs.
KEYWORDS

cross-species, data integration, drug abuse, genomics, GWAS, model organisms, multi-omic,
substance use disorders, working group
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I N T RO DU CT I O N

the state of substance use genetics, including the strengths and weaknesses of various approaches to genotype–phenotype associations in

On May 29–31, 2019, the National Institute on Drug Abuse (NIDA)

humans and model organisms. Most notably, researchers discussed

and the Joint Institute for Biological Sciences at the Oak Ridge

how joint data- and theory-driven studies using integrative cross-

National Laboratory (ORNL) hosted the Addiction Genetics and Epige-

species and multi-omics approaches could more rapidly discover and

netics Data Jamboree meeting at Oak Ridge, Tennessee. Over 30 sci-

translate mechanisms than relying upon genome-wide association

entists with expertise in genetics and genomics of substance use in

studies (GWAS) or model organisms alone. Over the course of 2 days,

human and model organisms gathered to discuss linking data and

researchers participated in thematic discussions that centered on the

results across systems that exploit genetics, genomics, epigenetics,

current state of knowledge, gaps in understanding and advantages

and other omics by leveraging innovative statistical methods and com-

and challenges of: (1) Data analyses using multi-species and multi-

putational tools. The meeting commenced with an open discussion of

omic data, (2) data integration methods/procedures, and (3) multi-
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omic data generation and sharing/accessibility. Meeting participants

diagnostic heterogeneity.21 Notably, the history of SUD and psychiat-

reconvened on the third day to summarize findings and since then

ric GWAS has shown that more common variants with modest effect

have reflected upon the field's latest findings around the meeting's

sizes can be identified and replicated when studies are well-powered.

topical areas in the preparation of the current document. Each

Yet, there are other substances of abuse for which we still lack suffi-

researcher brought their unique experience, perspective, and exper-

cient power (e.g., opioids22 and cocaine23) for unbiased identification

tise to these discussions, and a consensus was not always reached for

of the heritable components of susceptibility, severity, and relapse.

the best path forward on every topic. Not all authors of this report

For most common diseases, the number of genome-wide significant

necessarily endorse all ideas presented herein.

hits that are discovered increases sharply after a threshold sample size

This report aims to summarize the discussions by focusing on the

that ranges from about 10,000 to 100,000.24 In the case of psychiatric

state of science, including opportunities for more effective cross-talk

disease, it took 36,989 cases and 113,075 controls to identify 108 loci

and collaboration between human and model organism research com-

for schizophrenia.25 A simulation study by Walters et al. suggested

munities, as well as barriers to data acquisition and integration. Next,

that AUD and other related SUDs26 have effect size distributions simi-

we discuss the methods and tools used for genetic and genomic dis-

lar to major depression,27 a disease that required approximately

covery, their assumptions and limitations, as well as areas for improve-

10,000 cases to identify the first locus,28 and may require sample

ment needed to achieve rapid translation of genetic loci to identified

sizes between 55,000 and 130,000 cases (or more) to identify large

mechanisms and potential treatments. We review challenges of data

numbers of commonly occurring variants. 15 While biobanks and elec-

transportability and sharing (i.e., Findability, Accessibility, Interopera-

tronic health records provide opportunities for increasing sample sizes

bility, and Reusability data practices), for which there are interper-

for AUD, the ability to adequately assess illicit drug use disorder from

sonal, legal, and technological barriers of integrating diverse data

biobanks remains questionable. That said, steady progress is being

types. Finally, we describe some gaps to address in future programs

made for illicit substances. For example, a recently published GWAS

on substance use disorders (SUDs).

for opioid use disorder in the Million Veterans Program and two additional samples, obtained genome-wide significance for rs1799971 in
the gene encoding the mu-opioid receptor, OPRM1, with 8529 cases
and 71,200 opioid-exposed controls22 though additional work is

1.1 | Status of substance use and disorders
genetics and genomics

needed to validate these findings.
It is also important to note that identifying genetically-mediated

SUDs represent a pressing area of unmet medical, psychological, and

mechanisms of disease is also partially contingent on how well a phe-

social needs. In 2017, alcohol and illicit substance use and disorders

notype is defined so that it reflects relevant biological and environ-

resulted in 13,969 and 67,000 deaths (directly and indirectly) in the

mental variation. In human GWAS, phenotypic heterogeneity, which

United States, respectively,1 which was less than smoking ( 250,000

is evident in diagnostic classification, as well as the imprecision of

2

deaths), but more than liver disease (62,493 deaths) and diabetes

recall and self-report, has been shown to result in low heritability

(68,558 deaths).3 Worldwide, SUDs have a relatively early onset and

(in some instances) and specificity for disease prediction.29 Compared

4

contribute to approximately 21% of lost disability-adjusted life years

to humans, model organisms have the advantages of narrowly defined

(15% for smoking and second-hand smoke not counting comorbid

phenotypic assays applied to both experimental and control groups

1

drug use ), emphasizing the high societal and personal cost to affected

and objective measurements. However, animal models poorly reflect

individuals and communities. Twin- and family-based studies show

the interpersonal and quality of life aspects of human SUD.30 Human

5

that SUDs generally have moderate to high heritability,

with

studies using case–control and quantitative phenotypes of the most

sequence differences contributing to 50%–70% of variance in liability.

predominantly used substances, alcohol and tobacco, with sufficiently

Large-scale GWASs investigating hundreds of thousands of partici-

large sample size have recently confirmed suspected genetic media-

pants have become a reliable method to localize and identify genomic

tion of pharmacokinetic and pharmacodynamic pathways; studies also

regions, genes, and common and substance-specific nucleotide differ-

suggest greater relevance of single nucleotide variants expressed in

ences that contribute to the heritability of the many facets of

brain.31-33 Liu et al.18 found that all central-nervous-system-expressed

6-8

SUDs.

nicotinic receptor genes (except for CHRNA7) were significantly asso-

To date, there has been substantial progress in the characteriza-

ciated with one or more smoking phenotypes that they examined.

tion of the genetic etiology of human SUDs.9-13 Data sharing, meta-

This suggests that related phenotypes, such as age of smoking initia-

analysis, and very large sample sizes have begun to yield loci for

tion and cigarettes per day, may show overlapping but differential pat-

14-19

18,20

20

The past

terns of associations with relevant genetic variation. Therefore, it is

3 years have witnessed an escalation in these discoveries for instance,

important to examine a variety of different phenotypes, from case–

findings for alcohol use disorder (AUD) increased from one locus

control phenotypes to endophenotypes. For example, in a GWAS of a

(N = 14,904 cases) in 2018 to 29 independent variants in 2020

pharmacologically relevant phenotype for smoking, a measure of the

(N = 435,563, including >57,000 cases). These human GWASs have

rate of nicotine metabolism (the nicotine metabolite ratio [NMR]),

shown that SUDs are highly polygenic. This polygenicity may be par-

identified polymorphisms that account for nearly 40% of the pheno-

tially explained by human-specific evolutionary pressures and

typic variance in NMR,34 but these same loci do not have a similarly

alcohol-,

tobacco-,

and cannabis-related traits.
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large effect on nicotine dependence. Consequently, there is still a gap

in our understanding could be addressed using large and genetically

in understanding the broad and substance-specific mechanisms and

diverse samples (is being achieved for nicotine and alcohol, but not

the functional significance of DNA variants that have been discerned

other substances), better phenotyping, new computational methods,

to date using endo-, clinical-, and coarse-phenotypes and biomarkers.

and long-read sequencing technologies to capture and model causal

Some researchers at the meeting commented that mixed-linear-

genome variants, especially those (e.g., CNVs, insertions, deletions,

model-based and traditional GWAS and quantitative trait locus (QTL)

and inversions) not well captured by GWAS arrays; see Peterson

analyses alone cannot solve these phenotype limitations because the

et al.46 for a detailed discussion on opportunities for diversity in

variance structure of agglomerative phenotypes does not match that

GWAS. In addition, single-cell technologies, such as single-cell-RNA-

of the genome and the associated structures/tissues. Others coun-

seq, and complementary approaches toward studying regulatory

tered that well-powered GWAS complemented by new post-hoc com-

effects of variants, among others, will help to better uncover cell-type

putational methods (e.g., genomic structural equation modeling

35

and

specific networks involved in SUDs, as has been documented for

multivariate GWAS,36 to name a few) might surmount minimal

schizophrenia.47 Altogether, these types of systems-based approaches

phenotyping limitations. For a detailed example of deep phenotyping

that incorporate multiple layers of genomic and environmental data

issues in a complex psychiatric disorder, we recommend the recent

will require advanced methods, that may include multilevel machine

29

paper by Cai et al.

learning, deep learning, and explainable-artificial intelligence tech-

Based on these observations, researchers recognized that other

niques to name a few; and these model-free approaches will have to

methods should help complement and extend well-powered GWAS

accommodate features specific to the human genome, such as popula-

methods to address current knowledge gaps in the genetic architec-

tion substructure, which can confound association signals.48 Likewise,

ture of SUDs. A notable illustration arises from the characterization of

it will require a more comprehensive, integrated capture of

the complement C4 pathway in schizophrenia, which arose from a

population-scale data at multiple omics layers (genome, epigenome,

GWAS that identified a strong signal in the MHC locus but required

transcriptome, metabolome, microbiome) in both model organism and

deep, cross-species cellular and molecular experiments to explicate.

human studies (see Table 1). Costs for generating multi-omic data,

15,37

Previous studies

have also indicated this will require (1) larger

sample sizes, (2) better phenotyping, (3) more diverse samples,

including brain proteomics and metabolomics are falling rapidly and
making such programs possible.

(4) improved coverage of genetic variation by GWAS arrays or greater

Complementary to human GWAS, research using model organ-

emphasis on sequencing,38-40 and (5) more comprehensive system-

isms is amassing a large body of evidence supporting causal roles for

based models and hypotheses that incorporate epistasis (GxG), envi-

many genomic loci and gene variants related to SUDs (e.g., Taar1

ronmental factors, GxE, and many comorbidities. Systems-based and

for methamphetamine'49 APBA2 for addiction,46 XRCC5 for alcohol

multi-level studies would ideally model the complex nature of SUDs

dependence,50 and the use of CRISPy Critters for instance in

using multiple cofactors (and confounders) and take into account the

alcohol research51). Still, these findings probe only a small part of the

inevitability that many agglomerative phenotypes will be made up of

complex central nervous system (CNS) molecular and cellular net-

multiple mechanistically distinct sub-phenotypes. In addition to the

works affected by addictive substances. There is also deep sequence

more nuanced and precisely defined and quantified phenotypes and

data on shorter classes of DNA variants and expression data collected

cofactors (e.g., BMI for alcohol41) and confounders,42 such studies

in many contexts across large populations of key model organisms,

would also incorporate other forms of DNA variation and potential

including Drosophila (the Drosophila Genetic Reference Panel),52,53

non-linear (i.e., GxG and GxE) effects although recent studies have

mouse (Collaborative Cross, the Hybrid Mouse Diversity panel, and

suggested that most of the genetic variance for complex traits appears

the BXD family, collectively n >200 isogenic strains,54,55 and outbred

to be largely due to additive effects, with negligible dominance

mouse populations, including several heterogeneous stocks,56-59

effects, and an indeterminate amount of epistatic effects due to

advanced intercross lines60), and rat populations (e.g., Hybrid Rat

43

power and study design issues.

Still, it is worth noting that a negligi-

Diversity Panel and the National Institute of Health [NIH] heteroge-

ble genome-wide contribution of dominance effects does not pre-

neous stock,60 and outbred Sprague Dawley61,62). As a field, behavior

clude the existence of individual loci with a dominant mode of

geneticists, both human and animal modelers, are beginning to catalog

inheritance. While the importance of these different issues and

and even understand the function(s) of subsets of variants that alter

approaches was discussed, a diversity of opinions was expressed

protein-coding sequence, modulate transcript and protein isoforms, or

about GxG effects, and the group did not reach consensus.

change expression.63-65 However, although great progress has been

At the sequence level, many studies are also still missing signifi-

made, we highlight key gaps:

44

cant genetic diversity—particularly from non-European populations.

Even though copy number variant (CNV) studies of psychiatric disor-

1. the comparative invisibility of mobile element polymorphisms,

ders are becoming more commonplace,45 mobile element polymor-

some types of structural variants, simple tandem repeats, and rare

phisms, inversions and other types of structural variants are still

variants, including de novo mutations;

missed in GWAS—as are subsets of variants not tagged using standard

2. the problematic nature of aligning a sequence to a linear reference

GWAS arrays or incorrectly aligned to a single canonical reference

genome rather than to pangenomes that are savvy with respect to

genome. In short, recent insights from past studies highlight how gaps

sequence differences among individuals and ancestries; and
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TABLE 1

Considerations and Areas of Opportunity for Data Integration

Methodological
approach

Considerations in model
organism genetics

Considerations for human
genetics

GxE

Many populations provide
favorable recombination and
allele frequencies to provide
adequate power to detect G
x E effects

Consortia efforts (e.g.,
Psychiatric Genetics
Consortium [PGC],114
deCODE Genetics,115 UK
biobank,116 etc.) and
integration of electronic
health records can help
construct large sample sizes
for improved power to
detect G x E effects

Some human environments are
not possible to model in
animals

Some environments are
unethical to impose on
humans

QTL mapping in many
populations can provide
sufficient power to examine
other forms of DNA
variation and potential
nonlinear G x G effects
Structured panels of F1
progeny that place null
alleles on different genetic
backgrounds can identify G x
background interactions

GxG

Considerations for
reductionist models (human
and model organisms)

Areas of convergence

Not possible to mimic most
environmental effects (e.g.,
social interactions, early life
adversity, etc) in cell lines or
organ cultures

Animal models can test the
effects of a specific gene
implicated in human
GWAS across multiple
environments, or different
genes in the same
environment.
G x E hits from QTL mapping
can be used to prioritize
promising variants in
human GWAS that did not
meet significance
thresholds due stringent
corrections for multiple
testing

Need very large sample sizes
(> 1 million) to detect
potential nonlinear G x G
effects117

QTL mapping efforts should
utilize genetically diverse
populations in order to
better extrapolate results
across strains and species

Consortia efforts and private
direct to consumer
biotechnology companies
(e.g., 23 & me, ancestry.com)
may be key to amassing
large enough sample sizes
for improved power to
detect epistasis

If using CRISPR to study G x G
interactions, researchers
should test multiple genetic
backgrounds

-Development of new
statistical models to
detect G x G epistatic
interactions will improve
our understanding of the
polygenic nature of SUDs.
Use of genetically admixed,
mutant, and genetically
simple cohorts of model
organisms can identify
epigenetic modifiers

CRISPR allows for
simultaneous alteration of
multiple genes to examine G
X G interactions
Meta-analysis

Not commonly performed in
model organisms, but the
extendable nature of many
populations is favorable to
this approach

Meta-analysis has been key in
the successful identification
and replication of loci across
human studies, thus
increasing power and
reproducibility

Development and
application of metadata
standards and data
ontologies (such as
MONARCH) will be
critical to harmonize data
across organisms and data
types.
Improved data curation and
sharing will allow for
increased accessibility to
all researchers.
Meta-analytic studies using
omics data from both
mapping populations and
mutant animals can detect
and validate novel findings
entirely in silico.

Polygenic risk scores

Must account for allele
frequency differences across
populations

Must account for allele
frequency differences across
populations

Not widely implemented in
animal QTL mapping studies

PGS in humans have allowed
cross-trait and cross-sample
comparisons, greatly
enhancing our knowledge of
SUDs

Need to develop
methodology to integrate
PGS between animals and
humans to improve
translational, predictive
and clinical utility.

(Continues)
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(Continued)

Methodological
approach

Considerations in model
organism genetics

Considerations for human
genetics

Considerations for
reductionist models (human
and model organisms)

Areas of convergence

For translational studies, need
to limit PGS variants to
those with orthologs in
humans
Proteomics/
transcriptomics

Functional validation

Can be easily obtained in
animals from relevant
tissues, cell-types, and
timepoints (post-drug,
developmental)

Post-mortem brain tissue from
humans is confounded by
life histories, drug use
patterns, time elapsed
between death and brain
collection

Multiple bioinformatics
resources exist to integrate
omics results (GeneWeaver,
GeneNetwork)

Web-based repositories (GTEx,
BRAINEAC, CommonMind,
PsychENCODE) provide
valuable resources to
examine effects of gene
expression on disease

Multiple genetic resources
exist (CRISPR, KO,
transgenics, RNAi, etc) to
functionally validate genes
of interest in developmental, tissue-, and cell-specific
regions

Unethical to perform gene
editing studies in humans

Optogenetic and other brain
stimulation approaches can
isolate neurons, define
pathways relevant to traits
of interest

Transcranial magnetic
stimulation can excite/
silence brain regions in
humans, but is limited

Lesion studies can readily be
performed in animal models

Naturally occurring lesions can
be studied

Multi-omics data (genome,
epigenome, transcriptome,
proteome, metabolome,
microbiome) data in both
model organisms and
humans can improve our
understanding of GWAS
hits that fall in regulatory
regions
Single-cell RNAseq will help
uncover cell-type specific
networks involved in
SUDs
Animal models may identify
mobile element
polymorphisms,
inversions, and other
structural variants that can
later be studied in human
GWAS.
Network integration (such as
LOE, RWR) is key to
permit the full illumination
of patterns shared across
multi-omics datasets and
can be used to leverage
information across species
Exploiting publicly available
bioinformatics resources
can provide secondary
study replication/
validation, increase power,
and provide a priori
information for study
hypotheses and design
Functional validation studies
should test the effects of
gene manipulation on
multiple genetic
backgrounds

Model organisms provide
opportunities to test the
effects of a specific
gene(s) implicated in
human GWAS to help
elucidate the underlying
biology
Functional validation studies
may benefit from crossspecies analysis (yeast,
worms, flies allow for the
analysis of hundreds of
candidate genes)
-Development of efficient
and unbiased
computational workflows
(such as FUMA GWAS, HMAGMA, GeneWeaver,
PrediXcan/MetXcan) is
needed to rank top
variants and map their
cellular networks in both
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TABLE 1

(Continued)

Methodological
approach

Considerations in model
organism genetics

Considerations for
reductionist models (human
and model organisms)

Considerations for human
genetics

Areas of convergence
human and model
organisms

Environmental
control

Can more tightly control
environmental parameters

Diverse environmental and
lifestyle influences

Cannot accurately model some
human components (e.g.,
social elements) of
environments

Differing combinations of
psychiatric and other risk
factors

Improved statistical models
that better account for
confounds, Winner's
Curse, and cofactors/
covariates will enhance
translational potential for
both animal and human
research

Abbreviations: FUMA, functional mapping and annotation of genetic associations; GWAS, genome-wide association studies; H-MAGMA, hi-C-associated multimarker analysis of genomic annotation; LOE, lines-of-evidence; PGS, polygenic score; QTL, quantitative trait locus; RWR, random walk with restart; SUD, substance
use disorder.

3. the reliance on simple additive models that cannot detect or are

at the meeting acknowledged that animal QTL, and other methods

confounded by gene-by-gene epistatic interactions or cleanly dis-

(e.g., recombinant inbred strains55), can help make headway in parallel.

64,66

sect and unconfound GxE effects.

One area for further development includes refinement of efficient and
unbiased computational workflows to rank top variants and map their

Researchers at the meeting discussed gaps in knowledge and pos-

target genes and gene, molecular, and cellular networks.

sibilities for the next phase of functional discovery for substance use

Researchers at the meeting discussed strategies to make

and disorders, which will likely require (1) the construction of appropri-

advances in using integrative approaches, which could rapidly locate

ate resources for systematic evaluation of loci function in humans,

and translate loci for SUDs. These strategies combine data from

(2) quantitative experimental studies of SUDs in model organisms with

GWAS in humans with well-matched experimental work in model

a more realistic level of genetic complexity, (3) concerted multi-

organisms—both genetically admixed crosses and gene knockout and

disciplinary efforts to acquire additional samples for discovery/valida-

knock-in studies. Ideally, these studies would leverage a universal

tion, and (4) a shift towards causal models and quasi-experimental

platform for sharing current datasets from model organisms with

research designs in order to understand gene-by-environment, gene-

human GWAS findings, a resource currently lacking. At the time of

by-development, and epigenetic modifiers across a range of

this publication, data from model organism studies are largely isolated

genetically-admixed and genetically simple cohorts of model organisms.

by species and even by strain and type. As such, they are often far
from FAIR compliant67 and are just as hard to access and integrate as
GWAS data from heterogeneous human populations, which are not all

2 | T H E M E A : BR I D G I N G TH E G A P
BETWEEN HUMAN AND ANIMAL RESEARCH

shared on the NIH's database of Genotypes and Phenotypes (dbGaP)
or other repositories available to the scientific community. These realities further compound the challenge of rigorously combining human

2.1

|

Prioritizing variants for functional follow-up

and animal model data sets (see Section 4 Theme C discussion for
details).

In recent years, larger human GWAS have begun to produce a more
robust and reliable set of genomic loci and gene variants. Similarly, model
system studies complement these phenotype–genotype associations via
behavioral neurogenetic methods, but not without limitations (see
Table 1). Indeed, human and model organism studies offer varying

2.2 | Why data integration across species and
multiple omics is important for expansion, discovery,
and translation of genetic risk for SUDs

degrees of power and limitations to identify a gene or network for functional follow-up. For example, human GWAS require very large samples

While there are many differences between behaviors, body, and brain

to study phenotypes that may be less proximal to the biological ele-

structures of all model organisms and humans, there is still a high level of

ments. Model organisms require smaller sample sizes, but their individual

genomic and functional commonality that can be leveraged under tightly

single nucleotide polymorphisms (SNPs) and genes may not entirely map

controlled environmental and treatment conditions. In essence, a ran-

onto human biology and the substance use phenotypes that operate in a

domized controlled trial across multiple genotypes can usually be

complex, human environment. Given that the collection of larger, more

designed and implemented reasonably easily with model organisms.68

diverse GWAS samples for SUD phenotypes will require targeted data

Likewise, causal models can be constructed to evaluate potential con-

collection, especially in underrepresented populations, some researchers

founders by, for instance, comparing behavioral assays across
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constructed genetic backgrounds of varying disease susceptibility (see

chromatin structure,76 protein–protein interaction data, etc.) can be incor-

Table 1: areas of convergence). Molecular and cellular endophenotypes

porated to add evidence for the networks' biological plausibility; however

of SUDs are readily accessible in many model organisms. Conservation

several researchers advised caution as data limitations and improper han-

of functional genes and networks across species can provide genuine

dling could create biased results. Further sophisticated network layers can

insight of high translational relevance–particularly when the GWAS

be generated with the use of new explainable-AI tools that can find highly

searchlight has illuminated a small number of plausible genes and geno-

accurate linear and nonlinear multi-way associations within and across

mic regions. Because of differing evolutionary histories, individual vari-

omics layers;77 though, as shown in the case of machine learning using a

69,70

ants among humans and model organisms are often not conserved

;

candidate SNPs for opioid dependence, extreme care should be taken to

however, the prospects of comparing genetically engineered lines to

account for social inequities that permeate research practices and could

diverse populations of mice holds significant promise for disease map-

likely confound biological mechanisms under study.78 After integrating the

55

ping and detecting epistatic interactions.

This apparent gap in the liter-

networks from the different data inputs based on gene IDs, lines-of-

ature highlighted why analyses are best suited to be conducted at the

evidence (LOE) scoring79 methods offer a way to establish links between

level of genes, molecular networks, and gene sets. Still, attendees at the

the networks, with each link adding to the score for connecting layers.

meeting acknowledged that experimental models could complement

Explainable-AI approaches, such as iterative random forest-leave one out

these analyses by providing a reproducible resource to identify funda-

prediction (iRF-LOOP) are able to find linear and linear expression relation-

mental processes and modifiers that affect aspects of SUD with the goal

ships in expression datasets derived from population-scale RNA-seq

to transition as efficiently as possible to well-reasoned interventions that

datasets and are more accurate than traditional co-expression

reduce SUD burden. Gene network perturbations that are evident in cer-

approaches.77 These explainable-AI derived networks can be built from

tain model organism experiments and humans may highlight novel entry

publicly available datasets (such as GTEx) to provide tissue-specific regula-

points for pharmaceutical intervention and innovation that would be mis-

tory patterns. They can similarly be built of single-cell-RNA-seq datasets

sed by the study of humans alone (e.g., modulation of an associated pro-

to provide cell-type-specific regulatory networks. Of course, they can also

tein if variants are in a regulatory region). Further, identification of

be built from novel experimental data from individuals who were addicted

molecular and cellular networks that contribute to SUD risk, progression,

to opioids. These networks can be combined with networks derived from

and relapse will benefit from access to longitudinally collected datasets

other data types to form a multiplex network. For example, an

to strengthen causal inferences, define and test plausible models, and

explainable-AI-derived RNA expression network associated with opioid

refine treatment options on the basis of genotypes and diplotypes.

addiction in the nucleus accumbens (NAc) may link to a genome-wide

Human tissues, cells, and organoids are highly useful tools for eluci-

epistasis (GWES)-based network80 and a NAc-specific network assembled

dating molecular and cellular networks in human-relevant model sys-

from the GTEx, and may also connect through to a protein–protein inter-

tems but have fundamental limitations, especially with respect to

action network and signaling cascade network all through common gene

higher-order behavioral outcome variables that replicate aspects of

IDs. Subsequently, random walk with restart (RWR) approaches, which

human addiction. While formal proof of the roles of DNA variants is

use an advanced form of network-association that is not limited to explor-

most readily provided using gene-engineered animals or specific phar-

ing shortest paths or nearest neighbors, can jointly examine these multiple

macological treatments, it is vital to note that “necessary and sufficient”

heterogeneous multiplex networks while retaining the critical topological

causal criteria depend greatly on the genomic background.71 Moreover,

information present in each network.81 By jointly integrating multiple het-

gene-engineered models will ideally account for genetic diversity in

erogeneous data layers, one can score and rank candidate genes from

order to ensure that results are not only replicable but are likely to have

GWAS and genome-wide epistasis study (GWES) analyses using RWR-

external validity across species. While some researchers predicted that

based LOE algorithms. This can help to prioritize genes from GWAS/

data generated from these approaches would show greater consilience

GWES results and to provide mechanistic context for the resulting filtered

with the diversity of human behavioral outcomes, others contended

genes sets by way of subnetworks that include the links among members

that additional research is needed to understand which animal para-

of the filtered gene set and links to genes highly connected to members of

digms and tissues best characterize the basic behavioral properties and

the gene set in the network. This context greatly enhances mechanistic

neurobiological components of addiction, respectively.

interpretation and the creation of conceptual models that can be used to

Many researchers have begun to tackle the issue of variant prioritiza-

design validation experiments in human tissue or animal models. Because

tion by integrating multiple sources of information.72-74 Indeed, most

similar gene-based networks can also be generated from model organisms,

GWAS include detailed post-hoc analyses toward the identification of

they can also be integrated with human networks via ortholog projection

credible causal variants. Network integration is one method that can per-

in order to leverage information from multiple species.

mit the full illumination of patterns that are shared across gene sets
derived from single omics data (e.g., genetic variants, RNA-seq in bulk tissue, single-cell RNA-seq, chromatin immunoprecipitation sequencing
[ChIP-seq], ATAC-seq, methylome, etc.). Variant-based networks can be

2.3 | Challenges and knowledge gaps in crossspecies research

mapped onto genes, enabling a common basis for network integration: the
gene level. A range of public data (e.g., ChIP-seq from ENCODE, RNA-seq

There is heterogeneity in the behavioral phenotypes and paradigms

from the Genotype-Tissue Expression [GTEx] project,75 Hi-C data for

across humans and model organisms, respectively, that needs to be
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considered when attempting to identify the biobehavioral processes

exciting challenge but is (relatively) close at hand. Even more daunting

underlying substance use and disorders. Clinical diagnoses of SUDs in

challenges (and rewards) are presented by the ambitious goal of iden-

humans are based on assessments of drug-seeking, physical depen-

tifying neural pathways conserved between model organisms and

dence, and social disruption but often struggle to quantify each of

humans for addiction and its associated constellation of complex

these phenotypes (e.g., the problem of going from a polythetic diagno-

behaviors. Clearly, the molecular and bioinformatics tools that emerge

sis to understanding severity/impact of combinations of criteria on a

from tackling the first problem will be a starting point for attacking

person's life).

82

It is often the case that qualitative symptoms are

the second.

employed, and several combinations of criterion endorsements (i.e., 2
or more of 11 DSM-5 symptoms) could result in a diagnosis. This diagnostic heterogeneity (i.e., different case subjects meeting the criteria
for endorsing varying sets of symptoms) leads to challenges in genetic
mapping83-85 and alignment with unconditioned and conditioned

3 | T H E M E B : CU R R E N T T O O L S F O R
I N T E G R A T I O N OF GE N E T I C , E P I G E N E T I C ,
A ND P H E N O T Y P I C D A T A

quantitative traits used in animal models. In contrast, animal studies
place a high emphasis on measuring quantity/frequency and physio-

Several tools (e.g., methods, software, databases) currently exist and

logical dependence. Studies of alcohol and cannabis use disorders

are under active development to aid scientists in analyzing and inte-

have shown quantitative and qualitative differences between the

grating multiple types and streams of data from a wide variety of

genetics of consumption quantity and frequency and the genetics of

model organisms and diverse human populations. Here we highlight a

the disorders (e.g., impaired functioning, physical dependence, disrup-

few that facilitate multi-omics and cross-species research. For a more

12,86

tion of social responsibilities).

Likewise, a geneset derived from

tobacco exposure paradigms in rodents shows modest enrichment for

comprehensive list of tools please see the paper by Reynolds et al.90
Functional mapping and annotation of genetic associations

the SNP-heritability of human tobacco consumption.87 Notably,

(FUMA) was developed

inbred strain comparison/selective breeding studies have allowed sci-

pret GWAS results. The application integrates genome-wide summary

entists to examine the effects of genetic background on multiple

statistics with functional information, such as expression-QTL (eQTL)

related traits.88 Differences in the phenotypes assessed in humans

and chromosomal interaction mapping in a tissue-specific manner to

and rodents may therefore contribute to a partially disconnected

identify the most likely causal SNPs. FUMA uses 18 biological data

approach to understanding risk rather than a fully integrated

repositories (e.g., GTEx) and tools to functionally annotate GWAS hits.

approach, thus requiring detailed studies of consilience across pheno-

FUMA employs two gene-mapping strategies. First, it uses multi-

types and omic-phenotype associations. For example, even just within

marker analysis of genomic annotation (MAGMA) to aggregate SNP-

humans, recent studies suggest that the genetics of human alcohol

level statistics up to the gene level, which enables more facile follow-

consumption, particularly frequency of alcohol intake, is only partly

up network analyses. However, MAGMA does not take gene regula-

related to the genetics of alcohol problems (e.g., impaired functioning,

tory information into account when mapping SNPs to genes. Alterna-

physical dependence, disruption of social responsibilities).19 Likewise,

tively, FUMA allows GWAS annotation by leveraging Hi-C and eQTL

a geneset derived from tobacco exposure paradigms in rodents shows

data, leveraging available data resources including GTEx, Brain eQTL

modest enrichment for the SNP-heritability of human tobacco con-

Almanac (BRAINEAC),92 CommonMind,93 and PsychENCODE.94

87

sumption.

91

to annotate, prioritize, visualize, and inter-

Therefore, differences in phenotypes and their associated

Hi-C-associated multi-marker analysis of genomic annotation (H-

genetic architecture, whether within or across organisms, should be

MAGMA) was developed to overcome limitations in MAGMA.95 H-

taken into consideration, and leveraged when possible. As mentioned

MAGMA advances MAGMA by incorporating long-range (gene regu-

above, there is tremendous potential to build integrated, cross-species

latory) interactions defined by Hi-C in mapping SNPs to genes. Fur-

multi-omics networks that can serve to unify and utilize data and

ther, it adopts the genome-wide mapping capability of MAGMA and

extant knowledge from both humans and model organisms.

expands the gene set to follow-up for molecular and biological path-

There are several knowledge gaps that, if addressed, would help

way analysis. H-MAGMA has been developed on multiple Hi-C

inform whether genetic results for SUD phenotypes can be translated

datasets95,96—those obtained from human fetal brains, adult brains,

across species. These included understanding (1) the degree of con-

neurons, and glia sorted from the adult dorsolateral prefrontal cortex

cordance among model organism findings, as well as (2) the extent to

(DLPFC), iPSC-derived neurons, and iPSC-derived astrocytes. This

which model organism evidence generalizes to humans, (3) the con-

enables developmental stage and cell type-specific gene mapping.

textual implication of tissue, sex, and ancestry on these effects, and

GeneWeaver is a suite of database and analysis tools that inte-

(4) how unifying phenotypic definitions across databases can enhance

grate data from expression microarray, RNA-seq, QTL mapping,

sample sizes and data integration. To date, several studies have shown

GWAS, and mutation and perturbation screening experiments across

enrichment of mouse and rat gene sets (i.e., those that are differen-

species (yeast, worm, fly, zebrafish, mouse, rat, dog, human, and other

tially expressed in the presence of cocaine) in the human brain trans-

species).97-99 It also integrates protein–protein, molecular networks,

criptome for cocaine use disorder,

89

as well as human GWAS of

and regulatory relationships to impute biological functions of variants

tobacco/nicotine consumption.87 Identifying convergent genetic

and genes to phenotypes. In addition, GeneWeaver can assess molec-

mechanisms between humans and model organisms in SUDs is an

ular and trait relations through graphical network algorithms that
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leverage gene–gene and variant-variant comparison using complex,

while accounting for correlations. Extensions of this approach are

heterogeneous networks and random walk or network flow-based

now being used to transfer polygenic findings from GWAS between

approaches. Until recently, GeneWeaver has used a gene-based strat-

human populations, and the authors suggest that these techniques

egy to integrate data because convergence or conservation of mecha-

might allow translation between species in the future.105 These

nism across species has typically relied on gene orthology.

methods fall under the family of transcriptome-wide association study

Authoritative data resources, including model organism databases and

(TWAS)106 approaches more broadly (e.g., Fusion is a similar approach

the Alliance of Genome Resources, have cataloged orthologous genes

that can be performed on GWAS summary statistics).106

across species based on sequence alignments. Functional genomics
analysis systems, including GeneWeaver, have made use of these
reported orthologues to compare the results of genomic experiments
across species at the gene level. Transitive associations are made to

4 | T H E M E C : EN S U R I N G TH A T D A T A A R E
R E A D Y FO R I N T E G R A T I O N

infer cross-species orthology where sequence alignment has not
inferred a relationship (e.g., a Drosophila: zebrafish orthologue and

The long-term data curation and implementation of FAIR data princi-

zebrafish: mouse orthologue can be used to infer Drosophila: mouse

ples (https://www.go-fair.org/fair-principles/) is integral to the suc-

orthology). Although functional coding variants, such as missense vari-

cess of integrating human and model organism research and multi-

ants, are enriched among GWAS findings, most genome-wide signifi-

omic data. FAIR standards are particularly important. Without atten-

cant variants implicate noncoding regions.33 These noncoding variants

tion to data accessibility, many large and small SUD-related data sets

are poorly conserved at the sequence level, and their functional inter-

risk evaporating over a relatively short period of time—often only 5–

pretation presents a major challenge for the field. New approaches

10 years. This is particularly true of animal model data that tends to

are being developed by the GeneWeaver project for mapping noncod-

be highly granular and often siloed. Data sharing issues aside, there is

ing variants across species based on functional similarity and target

a need for (inter)national storage and curation efforts because those

orthology using combined genomic data sources. These methods are

aspects are typically beyond the scope of most research projects.

being applied to prioritize GWAS-identified variants based on evi-

Continued access to data, regardless of its presumed value, is key to

dence obtained in model organisms.

leveraging future technological advances. There are, however, notable
cases where advances in computing capacity and statistical methods
greatly improve the value of older data. For example, phenotype data

3.1

|

GeneNetwork

on drugs of abuse acquired over three decades ago can now be reanalyzed using new mapping algorithms (e.g., linear mixed models) and

GeneNetwork is an interactive system for genome-to-phenome analy-

full genome sequence data. For example, data generated by a team at

sis, QTL mapping, and network integration. This resource incorporates

ORNL a decade ago68 can be remapped today to generate signifi-

large genetic, multi-omic, and phenotype data sets for highly diverse

cantly stronger and even novel results than they did initially.

animal model populations such as the BXD and CC lines of mice, the

Participants discussed current knowledge gaps related to the

HXB and HS rats, and several large number transcriptome data sets,

development of metadata standards and data ontologies in order to

including GTEx. GeneNetwork integrates 40 years of animal model

move research forward. For instance, the lack of standards for

data relevant to NIDA, NIAAA, NINDS, and NIMH missions, starting

describing disease phenotypes, such as those developed by the MON-

with catalytic studies by Crabbe, McClearn, Hitzemann and Flint—

ARCH initiative (Mondo disease ontology and Human Phenotype

especially data on behavioral variation and its linkage to gene and pro-

Ontology [HPO];107,108) and the limited amount and quality of derived

tein expression in the central nervous system.55,68,100 The great

phenotypes from electronic health records. Metadata helps with

majority of data in GeneNetwork is both open and FAIR-compliant

findability, interoperability, and usability. Because of this, participants

and can be downloaded or used on-site in combination with powerful

emphasized that distribution platforms and curation tools that make

mapping modules that include R/qtl,101,102 and the Bayesian network

metadata searchable urgently need further development. Overcoming

webserver.103

these limitations would involve the identification of missing summary
metadata fields for human data in dbGaP, as well as making prior
results and data accessible both in name and in practice. Still, there is

3.2

|

PrediXcan/MetaXcan

not a standard process for making data more findable and readable.
Participants discussed several possible approaches for making data

PrediXcan was developed as a gene-based association test that priori-

more searchable, such as using a Digital Object Identifier (DOI),

tizes genes likely to be causal for the phenotype, using predicted gene

machine-readable identification number, and Research Resource Iden-

expression levels, most often with GTEx as the reference.104 S-

tifiers (RRIDs)109 as possible strategies to achieving data integration.

PrediXcan is a variation of this test that uses summary statistics

As with all large-scale data endeavors, the researchers recognized a

instead of individual-level data. MultiXcan and S-MultiXcan are multi-

limitation around encryption software that would enable accessibility

variate approaches (in contrast to the single-tissue approaches of Pre-

of primary raw data and allow searches across databases without the

diXcan/S-PrediXcan) that integrate measurements across tissues

loss of de-identification. A major benefit of overcoming this limitation
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would be the ability to work with raw data using alternative methods

tools. Continued research in integrative platforms will allow the exam-

that meta-analysis does not permit. Similarly, researchers acknowl-

ination of various use cases that will help develop an understanding of

edge the limited number of application programming interfaces (APIs)

the difficulties and opportunities in data integration. As the goal is to

to enable interactions between data, applications, and devices. APIs

develop a plausible set of gene networks/sets from robust GWAS and

deliver data and facilitate connectivity between devices and programs.

fine mapping studies in mice and humans, it will be important to con-

Compelling prototype solutions are described above, but issues

sider the nuances of mapping top results based solely on positional

remain in the widespread integration and adoption of these systems.

data. For example, previous SUD GWASs limited annotations to genes

The biggest challenges are dynamic updating and organization of data

nearest to the lead SNP, and only more recently have studies begun

for sharing and discovery as well as connecting across organisms and

to include tissue-specific annotation methods such as H-MAGMA and

data types (e.g., sequence, epigenomic, etc.). Integration between

PrediXscan, to name a few. Many researchers are working on system-

graphical and relational databases remains a problem to be solved. To

atic multi-omic integration approaches to fine map complex genetic

address these major challenges, participants discussed areas for

loci and nominate target genes. Reports on the progress of these

improvement, including a lack of understanding of the following:

efforts began at the Genetics and Epigenetics of Addiction (January
13–14, 2020) and are available at https://www.drugabuse.gov/

1. The degree of modularity and interoperability of existing data anal-

research/research-data-measures-resources/genetics-epigenetics-

ysis software that can be used to facilitate the integration of ChIP-

ccrt/nida-genetics-consortium-ngc/nida-genetic-consortium-

seq, DNA methylation, Hi-C, RNA-seq, splice variants, and struc-

meetings-abstracts. Second, we need an increased understanding of

tural variants information.

the neurotoxic and behavioral effects of drugs. This continuously

2. How gene network, epistasis, and genetic modifiers affect substance use outcomes.
3. How chromatin organization varies across human brain regions
and in different cell types.

evolving body of literature will facilitate computational experiments
to identify gene variants in underpowered GWAS. Integrative analyses
in humans that include model organism data could also be applied to
GWAS data as have been realized to date using Bayesian approaches

4. Ancestry differences in gene regulation.

to optimize gene identification using functional categories in genet-

5. How chromatin (Hi-C) and methylation (H3K27ac) data can be

ics111 and cis- and trans-eQTL information in transcriptomics.112

combined to predict gene expression with higher accuracy.

This Data Jamboree meeting represents a pivotal point in an

6. How models using protein–protein interaction (or similarly relevant

ongoing process of information sharing that reflects the interdisciplin-

omic data) data can help to improve the performance of existing

ary nature of addiction genetics research. Notably, it builds on the

genetic prediction tools.

previous report by Cates et al.,113 that emphasized the importance of

7. How to access raw primary data while maintaining de-identification.

harmonizing phenotypes and methods of analysis among studies.
Even though geneticists at this meeting did not always agree on
the ideal course of action for the next phase of discovery, the debate

5 | CONCLUSIONS AND FUTURE
DIRECTIONS

and dialog, spurred by a shared commitment towards identifying tangible genetic targets, resulted in several new directions for human and
model organism research.

Genetics in human and animal models is now providing significant
insights into molecular causes of addiction and SUDs. However, these
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